HC Wainwright reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Voyager Therapeutics’ Q3 2024 earnings at ($0.31) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.97) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.20) EPS.
VYGR has been the topic of a number of other research reports. Wedbush dropped their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th. Oppenheimer restated an outperform rating and issued a $18.00 price target on shares of Voyager Therapeutics in a report on Wednesday, May 15th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a buy rating to a hold rating in a research note on Monday, May 13th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $17.83.
View Our Latest Research Report on Voyager Therapeutics
Voyager Therapeutics Stock Performance
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. On average, analysts forecast that Voyager Therapeutics will post -1.47 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Voyager Therapeutics
Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock valued at $747,000 after purchasing an additional 5,365 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics during the second quarter worth $12,668,000. Hsbc Holdings PLC purchased a new stake in shares of Voyager Therapeutics during the second quarter valued at $128,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Voyager Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 143,523 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,816 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Featured Stories
- Five stocks we like better than Voyager Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- How to Invest in the FAANG Stocks
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Invest in the Best Canadian StocksĀ
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.